

30-Day Countdown – Phase III, Lift 2: Retirement of the Transition Policy for Beneficiaries 22 Years of Age and Older

March 21, 2023

What Pharmacy Providers and Prescribers Need to Know

On April 21, 2023, Phase III, Lift 2 (P3/L2) will be implemented, lifting the Transition Policy for 17 Standard Therapeutic Classes (STCs). This is the second in a series of lifts to retire or phase out the grandfathering of historical prior authorizations (PAs) and claims by lifting the override of **NCPDP Reject Code 75 – Prior Authorization Required**.

The following 17 STCs will be impacted with implementation of P3/L2 on April 21, 2023:

| Phase III, Lift 2 (P3/L2) Drug Classes * | | | |
|--|-----------------------|---------------------|--------------------|
| Contraceptives and | Ophthalmic, Nasal, | Thyroid Agents | Topical Anesthetic |
| Hormones | and Otic Preparations | (STC 55, 57) | Agents |
| (STC 59 – 64) | (STC 19, 20) | | (STC 45) |
| Dermatologic Agents | Biologic Agents | Glucocorticoids and | Anti-Parkinson's |
| (STC 93, 95) | (STC 90) | Corticotropins | (STC 9) |
| | | (STC 50, 51) | |

* STC refers to the Standard Therapeutic Classification number.

- Beneficiaries 21 years of age and younger are exempt from Phase III: Retirement of the Transition Policy.
- Enteral nutrition products for beneficiaries of all ages are also exempt from Phase III: Retirement of the Transition Policy.

What Pharmacy Providers and Prescribers Need to Do

If a beneficiary is currently receiving a medication in the STCs identified for P3/L2 as listed in the table above, pharmacy providers and prescribers should prepare for the retirement of the Transition Policy in the following ways:

- 1. Consider covered therapies that may not require a PA, if clinically appropriate. Review the following:
 - Medi-Cal Rx Contract Drugs Lists & Covered Products Lists
 - Medi-Cal Rx Approved NDC List
 - Prescribers: Refer to your ePrescribing application.
- 2. If a change in therapy is not appropriate, submit a PA request via one of the approved Medi-Cal Rx Submission Methods:
 - <u>CoverMyMeds</u>®
 - Medi-Cal Rx Secured Provider Portal
 - NCPDP P4 Transaction
 - Fax
 - U.S. Mail

Resources

- For more information about Medi-Cal Rx Reinstatement, visit the <u>Medi-Cal Rx Education &</u> <u>Outreach</u> page on the <u>Medi-Cal Rx Web Portal</u> and select **Medi-Cal Rx Reinstatement**.
- Review the <u>Medi-Cal Rx Reinstatement of Prior Authorizations and Retirement of the</u> <u>Transition Policy: Phases II, III, and IV</u> slide deck.
- Review <u>Medi-Cal Rx Phased Reinstatement Frequently Asked Questions (FAQs)</u>.
- Review the <u>Medi-Cal Rx Reinstatement Phases II–III</u> webinar recording.
- Review the <u>30-Day Countdown Phase III, Lift 1: Retirement of the Transition Policy for</u> <u>Beneficiaries 22 Years of Age and Older</u> alert.
- Refer to the <u>Medi-Cal Rx Bulletins & News</u> and <u>Medi-Cal Rx Forms & Information</u> pages of the <u>Medi-Cal Rx Web Portal</u> for guidance to successfully submit PAs.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at <u>MediCalRxEducationOutreach@magellanhealth.com</u>.